N-{5-[(7-{[(2S)-2-Hydroxy-3-piperidin-1-ylpropyl]oxy}-6-methoxyquinazolin-4-YL)amino]pyrimidin-2-YL}benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-{5-[(7-{[(2S)-2-Hydroxy-3-piperidin-1-ylpropyl]oxy}-6-methoxyquinazolin-4-YL)amino]pyrimidin-2-YL}benzamide
• 英文别名: N-[5-[[7-[(2S)-2-hydroxy-3-piperidin-1-ylpropoxy]-6-methoxyquinazolin-4-yl]amino]pyrimidin-2-yl]benzamide
• 化学式: C₂₈H₃₁N₇O₄
• 分子量: 529.6
• InChiKey: WHHFZOIADLFZRX-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• THERAPEUTIC QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1218355A1

  公开（公告）日：2002-07-03
• US7214518B2
  申请人：——

  公开号：US7214518B2

  公开（公告）日：2007-05-08
• US7235559B1
  申请人：——

  公开号：US7235559B1

  公开（公告）日：2007-06-26
• [EN] THERAPEUTIC QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES THERAPEUTIQUES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2001021597A1

  公开（公告）日：2001-03-29

  A compound of formula (I) or a salt, ester, amide or prodrug thereof; where X is O, or S, S(O), S(O)2 or NR6 where R6 is hydrogen of C¿1-6?alkyl; R?5¿ is an optionally substituted 6-membered aromatic ring containing at least one nitrogen atom, and R?1, R2, R3, R4¿ are independently selected from halogeno, cyano, nitro, C¿1-3?alkylsulphanyl, -N(OH)R?7¿-(wherein R7 is hydrogen, or C¿1-3?alkyl), or R?9X1¿-(wherein X1represents a direct bond, -O-, -CH¿2?-, -OC(O), -C(O)-, -S-, -SO-, -SO2-, -NR?10¿C(O)-, -C(O)NR11-, -SO¿2?NR?12-, -NR13SO¿2- or NR14-(wherein R?10, R11, R12, R13 and R14¿ each independently represents hydrogen, C¿1-3?alkyl or C1-3alkoxyC2-3alkyl), and R?9¿ is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy; provided that at least one of R2 or R3 is other than hydrogen. These compounds inhibit aurora 2 kinase and are useful in the preparation of medicaments for the treatment of proliferative disease such as cancer.